免疫介导炎症性疾病中的联合治疗:基于巴黎公立医院援助机构临床数据仓库的研究
基于巴黎公立医院临床数据仓库的多中心观察性研究,纳入125例联合治疗患者及251例匹配单药对照,中位随访15个月。联合治疗与单药治疗的严重不良事件和严重感染发生率无统计学差异,但阿巴西普+JAK抑制剂、抗IL-1和抗CD20联合方案与严重不良事件风险升高独立相关。
要点
- 联合治疗患者1年严重不良事件累积发生率为29%(95%CI 21-38),严重感染为24%(95%CI 16-32)。
- 阿巴西普+JAK抑制剂联合治疗与严重不良事件风险升高独立相关(HR 6.81,95%CI 1.88-24.68)。
- 抗IL-1联合方案(HR 4.82,95%CI 1.17-19.89)和抗CD20联合方案(HR 4.03,95%CI 1.22-13.31)也与严重不良事件风险升高独立相关。
核心结论
- 联合治疗总体严重不良事件风险与单药治疗相比似乎未见大幅增加,但某些联合方案需谨慎。
- 联合治疗的组成似乎可预测安全性结局。
研究设计与样本
- 多中心观察性研究,使用巴黎公立医院援助机构临床数据仓库,纳入免疫介导炎症性疾病联合治疗患者及匹配的单药治疗对照组。
- 从42071例免疫介导炎症性疾病患者中,2017年至2022年间在125例患者中识别出131个联合治疗线(中位年龄36岁,女性58%)。
- 匹配的单药治疗对照251例。
主要发现
- 最常见的免疫介导炎症性疾病为炎症性肠病(48.8%)、结缔组织病(23.2%)、炎症性肌病(14.4%)和血管炎(11.2%)。
- 中位随访15个月[IQR 19]后,30例(24%)患者出现严重感染,5例(4%)肿瘤,4例(3.2%)静脉血栓栓塞,3例(2.4%)急性冠脉综合征,7例(5.6%)死亡。
- 严重不良事件和严重感染的1年累积发生率分别为29%(95%CI 21-38)和24%(95%CI 16-32)。
- 校正混杂因素后,联合治疗患者与单药治疗对照(n=251)相比,生存率、严重不良事件发生率和严重感染发生率无统计学差异。
- 多变量分析中,阿巴西普+JAK抑制剂(HR 6.81,95%CI 1.88-24.68)、抗IL-1联合方案(HR 4.82,95%CI 1.17-19.89)和抗CD20联合方案(HR 4.03,95%CI 1.22-13.31)与严重不良事件风险升高独立相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of different biological and targeted synthetic DMARDs (i.e., combotherapy) has recently emerged in the management of immune-mediated inflammatory diseases (IMID). However, real-life data across specialities and prognostic factors related to combotherapy are lacking. METHODS: Multicenter observational study conducted using the Clinical Data Warehouse from Paris Hospitals' Public Assistance including IMID patients under combotherapy, and a matched monotherapy control group. The primary endpoint was the occurrence of serious adverse events (SAE), defined by severe infections, major cardiovascular events, neoplasia and mortality (all-cause). RESULTS: From 42,071 subjects having an IMID, 131 combotherapy lines were identified among 125 patients (median age of 36 years, 58 % females) between 2017 and 2022. The most frequent IMIDs were inflammatory bowel disease (48.8 %), connective tissue diseases (23.2 %), inflammatory myopathies (14.4 %) and vasculitis (11.2 %). After a median follow-up of 15 months [IQR 19], 30 (24 %) patients presented severe infections, 5 (4 %) neoplasia, 4 (3.2 %) venous thromboembolism, 3 (2.4 %) acute coronary syndromes and 7 (5.6 %) deaths. The 1-year cumulative incidence of SAE and severe infections were 29 % (95 %CI 21-38), and 24 % (95 %CI 16-32), respectively. The survival, incidence of SAE and severe infections were not statistically different from combotherapy patients compared to monotherapy controls (n=251) after adjustment for confounders. In multivariate analyses, we found abatacept + JAKi (HR 6.81, 95 %CI 1.88-24.68), anti-IL-1-based (HR 4.82, 95 %CI 1.17-19.89) and anti-CD20-based (HR 4.03, 95 %CI 1.22-13.31) combotherapies to be independently associated with an increased risk of SAE. CONCLUSION: The overall risk of SAE under combotherapy does not seem greatly increased compared to monotherapy, but certain combinations warrant caution. The combotherapy composition seems predictive of safety outcomes.
引用
- Gérard AL, Vieira M, Cohen A, et al. Combotherapies in immune-mediated inflammatory diseases: A study using the Clinical Data Warehouse from Paris Hospitals' Public Assistance. Semin Arthritis Rheum. 2025. PMID: 39978288. doi:10.1016/j.semarthrit.2025.152660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。